Imugene Receives Approval to Start Gastric Cancer Study
Filed with ASX · · 2 pages · English
Earlier from Imugene
- Imugene Receives Institutional Review Board approval
- Regulatory package submission for Her-Vaxx in Hong Kong
- Imugene Announces Successful Capital Raising
- Manufacturing Update
- Partnership to Develop Mimotope Immuno-Oncology Platform
Later from Imugene
- Imugene Final Cancer Vaccine Doses Delivered to GMP Depot
- Imugene successfully completes preclinical animal studies
- Imugene receives $1.3m R&D Tax Refund
- Imugene Share Placement raises $3.2 million
- Imugene Commences HER-Vaxx Phase 1b/2 Gastric Cancer Study
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene